Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
| Autor: | Alkner, S, Jensen, M-B, Rasmussen, B B, Bendahl, P-O, Fernö, M, Rydén, L, Mouridsen, H, Hoyer, Ute |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research Estrogen receptor Amplified in breast cancer 1 (AIB1) Nuclear Receptor Coactivator 3 0302 clinical medicine Breast cancer Aromatase Predictive marker biology Letrozole Hazard ratio Prognosis Clinical Trial Up-Regulation Gene Expression Regulation Neoplastic Postmenopause Treatment Outcome 030220 oncology & carcinogenesis Female Randomized trial medicine.drug medicine.medical_specialty medicine.drug_class Antineoplastic Agents Breast Neoplasms 03 medical and health sciences Double-Blind Method Internal medicine Nitriles medicine Journal Article Biomarkers Tumor Humans Aromatase inhibitor BIG 1-98 business.industry Triazoles medicine.disease Tamoxifen 030104 developmental biology Tissue Array Analysis biology.protein Neoplasm Grading business |
| Zdroj: | Breast Cancer Research and Treatment Alkner, S, Jensen, M-B, Rasmussen, B B, Bendahl, P-O, Fernö, M, Rydén, L, Mouridsen, H, Danish Breast Cancer Cooperative Group & Hoyer, U 2017, ' Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98 ', Breast Cancer Research and Treatment, vol. 166, no. 2, pp. 481-490 . https://doi.org/10.1007/s10549-017-4416-0 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-017-4416-0 |
| Popis: | PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer.METHOD: AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group's trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs).RESULTS: Forty-six percent of the tumors had a high AIB1 expression. In line with previous studies, AIB1 correlated to a more aggressive tumor-phenotype (HER2 amplification and a high malignancy grade). High AIB1 also correlated to higher estrogen receptor expression (80-100 vs. 1-79%), and ductal histological type. High AIB1 expression was associated with a poor disease-free survival (univariable: hazard ratio 1.35, 95% confidence interval 1.12-1.63. Multivariable: hazard ratio 1.29, 95% confidence interval 1.06-1.58) and overall survival (univariable: hazard ratio 1.34, 95% confidence interval 1.07-1.68. Multivariable: hazard ratio 1.25, 95% confidence interval 0.99-1.60). HER2 did not seem to modify the prognostic effect of AIB1. No difference in treatment effect between tamoxifen and letrozole in relation to AIB1 was found.CONCLUSIONS: In a subset of the large international randomized trial BIG 1-98, we confirm AIB1 to be a strong prognostic factor in early breast cancer. Hence, although tumor AIB1 expression does not seem to be useful for the choice of tamoxifen versus an aromatase inhibitor in postmenopausal endocrine-responsive breast cancer, AIB1 is an interesting target for new anti-cancer therapies and further investigations of this biomarker is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink